Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Sada Pillay"'
Autor:
Michael Lahn, N. Sada Pillay, Jonathan Michael Yingling, Ann Cleverly, Colin Miles, Ivelina Gueorguieva, Anja Stauber, Jordi Rodon
Publikováno v:
British Journal of Clinical Pharmacology. 77:796-807
Aims To identify prospectively a safe therapeutic window for administration of a novel oral transforming growth factor β (TGF-β) inhibitor, LY2157299 monohydrate, based on a pharmacokinetic/pharmacodynamic (PK/PD) model. Simulations of population p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b7463534de62bbe1014e47ecdb44fe3
https://doi.org/10.1111/bcp.12256
https://doi.org/10.1111/bcp.12256
Autor:
Leo Mascarenhas, Michael W. Bishop, Steven G. DuBois, Donna E. Levy, Datchen Fritz Tai, Sada Pillay, Theodore W. Laetsch
Publikováno v:
Journal of Clinical Oncology. 35:TPS2599-TPS2599
TPS2599 Background: Olaratumab (LY3012207, IMC-3G3), a PDGFRα antagonist, is a targeted human IgG1 monoclonal antibody that specifically binds PDGFRα, blocking PDGF-AA, -BB, and -CC binding and receptor activation. Preclinical studies of olaratumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b3030ea24119f74e71bbc982721eda2
https://doi.org/10.1200/jco.2017.35.15_suppl.tps2599
https://doi.org/10.1200/jco.2017.35.15_suppl.tps2599
Autor:
Ivelina, Gueorguieva, Ann L, Cleverly, Anja, Stauber, N, Sada Pillay, Jordi A, Rodon, Colin P, Miles, Jonathan M, Yingling, Michael M, Lahn
Publikováno v:
British journal of clinical pharmacology. 77(5)
To identify prospectively a safe therapeutic window for administration of a novel oral transforming growth factor β (TGF-β) inhibitor, LY2157299 monohydrate, based on a pharmacokinetic/pharmacodynamic (PK/PD) model. Simulations of population plasma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::57d1c3afbd81b8e942e87e2b02dbe358
https://pubmed.ncbi.nlm.nih.gov/24868575
https://pubmed.ncbi.nlm.nih.gov/24868575
Autor:
Volker, Wacheck, Michael, Lahn, Gemma, Dickinson, Wolfgang, Füreder, Renata, Meyer, Susanne, Herndlhofer, Thorsten, Füreder, Georg, Dorfner, Sada, Pillay, Valérie, André, Timothy P, Burkholder, Jacqueline K, Akunda, Leann, Flye-Blakemore, Dirk, Van Bockstaele, Richard F, Schlenk, Wolfgang R, Sperr, Peter, Valent
Publikováno v:
Cancer Management and Research
Background: Acute myeloid leukemia (AML) is a life-threatening malignancy with limited treatment options in chemotherapy-refractory patients. A first-in-human dose study was designed to investigate a safe and biologically effective dose range for LY2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9f331a7254839c38b83ceacaf9c71738
https://pubmed.ncbi.nlm.nih.gov/21625399
https://pubmed.ncbi.nlm.nih.gov/21625399
Autor:
Ivelina Gueorguieva, Durisala Desaiah, Tamara Nadal, Mark Kozloff, Rocio Garcia Carbonero, Al Blunt, Ann Cleverly, Michael Lahn, Teresa Macarulla, Sada Pillay, Josep Tabernero
Publikováno v:
Journal of Clinical Oncology. 31:2563-2563
2563 Background: Based on animal studies, the combination of a TGF-β inhibitor and gemcitabine is expected to enhance antitumor activity of gemcitabine. Hence, we started a combination study of LY with gemcitabine to assess the safety of this combin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60091d3d10b709ca9e397a5088c6f348
https://doi.org/10.1200/jco.2013.31.15_suppl.2563
https://doi.org/10.1200/jco.2013.31.15_suppl.2563
Autor:
José Baselga, Emiliano Calvo, Joan Seoane, Michael Lahn, Jordi Rodon, Elisabet Sicart, Irene Brana, Juan Manuel Sepúlveda, Analia Azaro, Luis Paz-Ares, Ann Cleverly, Jaishri O. Blakeley, Sada Pillay, Ivelina Gueorguieva, Michael A. Carducci, Durisala Desaiah, Matthias Holdhoff
Publikováno v:
Journal of Clinical Oncology. 31:2016-2016
2016 Background: Activated TGF-ß signaling has been associated with poor survival in several tumors, including glioma (GM). Hence, we investigated the safety, PK and antitumor responses of the novel TGF-ß inhibitor LY in cancer patients, mainly in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b443515002504dd0c98136138adadbc
https://doi.org/10.1200/jco.2013.31.15_suppl.2016
https://doi.org/10.1200/jco.2013.31.15_suppl.2016
Autor:
Jaishri O. Blakeley, Luis Paz-Ares, José Baselga, Irene Brana, Sada Pillay, Ann Cleverly, Joan Seoane, Jordi Rodon Ahnert, Michael Lahn, Analia Azaro, Juan Manuel Sepúlveda, Ivelina Gueorguieva, Michael A. Carducci, Matthias Holdhoff
Publikováno v:
Journal of Clinical Oncology. 30:2042-2042
2042 Background: Activated TGF-b signaling has been associated with poor survival in several tumors, including glioma. TGF-b inhibitors are expected to improve outcome. Part B of this Phase I trial assessed safety, pharmacokinetics, pharmacodynamics,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1765bea6cb6e01cc68ba814ac873b4cd
https://doi.org/10.1200/jco.2012.30.15_suppl.2042
https://doi.org/10.1200/jco.2012.30.15_suppl.2042
Autor:
Joan Seoane, Michael Lahn, Irene Brana, J. Baselga, Elisabet Sicart, Emiliano Calvo, Ann Cleverly, Ivelina Gueorguieva, Michael A. Carducci, Matthias Holdhoff, J. Rodon Ahnert, Sada Pillay, Jaishri O. Blakeley
Publikováno v:
Journal of Clinical Oncology. 29:3011-3011
3011 Background: Activated TGF-b signaling has been associated with poor survival in several tumors, including glioma, hepatocellular and pancreatic cancer. TGF-b inhibitors are expected to improve...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86e7e8edf7806e9c9917b1433f2a142c
https://doi.org/10.1200/jco.2011.29.15_suppl.3011
https://doi.org/10.1200/jco.2011.29.15_suppl.3011
Autor:
Gueorguieva I, Cleverly AL, Stauber A, Sada Pillay N, Rodon JA, Miles CP, Yingling JM, Lahn MM
Publikováno v:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2014 May; Vol. 77 (5), pp. 796-807.